A share price of Adc Therapeutics SA [ADCT] is currently trading at $5.09, up 1.80%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ADCT shares have gain 14.64% over the last week, with a monthly amount glided 2.41%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 4, April 2024, ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. In a post published today on Yahoo Finance, Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients and early signs of anti-tumor activity.
From an analyst’s perspective:
Adc Therapeutics SA [NYSE: ADCT] stock has seen the most recent analyst activity on March 28, 2024, when Guggenheim initiated its Buy rating and assigned the stock a price target of $11. Previously, JP Morgan upgraded its rating to Neutral on August 10, 2023. On April 24, 2023, downgrade downgraded it’s rating to Underperform and revised its price target to $2 on the stock. CapitalOne started tracking the stock assigning a Overweight rating and suggested a price target of $12 on December 06, 2022. BofA Securities downgraded its rating to a Neutral and reduced its price target to $7 on November 09, 2022. JP Morgan started tracking with a Overweight rating for this stock on September 21, 2022, and assigned it a price target of $5. In a note dated September 09, 2022, Morgan Stanley downgraded an Equal-Weight rating on this stock and revised its target price from $17 to $11.
Adc Therapeutics SA experienced fluctuations in its stock price throughout the past year between $0.36 and $6.04. Currently, Wall Street analysts expect the stock to reach $13.33 within the next 12 months. Adc Therapeutics SA [NYSE: ADCT] shares were valued at $5.09 at the most recent close of the market. An investor can expect a potential return of 161.89% based on the average ADCT price forecast.
Analyzing the ADCT fundamentals
Trailing Twelve Months sales for Adc Therapeutics SA [NYSE:ADCT] were 69.56M which represents -75.94% decline. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -2.43%, Pretax Profit Margin comes in at -2.89%, and Net Profit Margin reading is -3.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.67, Equity is 5.52 and Total Capital is -0.59. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.77.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.89 points at the first support level, and at 4.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.34, and for the 2nd resistance point, it is at 5.58.
Adc Therapeutics SA [ADCT] reported earnings per share of -$1.03 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.5/share, meaning a difference of -$0.53 and a surprise factor of -106.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.58 per share as compared to estimates of -$0.63 per share, a difference of $0.05 representing a surprise of 7.90%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Adc Therapeutics SA [NYSE:ADCT] is 4.97. As well, the Quick Ratio is 4.73, while the Cash Ratio is 4.12. Considering the valuation of this stock, the price to sales ratio is 6.04.
